The Dental and Oral Significance of Hutchinson-Gilford Prfogeria Syndrome

Authors

  • Safa Saeed College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Jawaher Abdulaziz Alhababi College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Fatimah Alanazi College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Amal Albarrak College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Halh Alabdulmonem College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Alanoud Inad Alenazi College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Maha Alsane College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
  • Myle Akshay Kiran 1-Department of Scientific Clinical Research, Acharya Nagarjuna University, PIPS, Andhra Pradesh, West Godavari District, India /2-Department of General and Alternative Medicine, Acharya Nagarjuna University, PIPS, Andhra Pradesh, West Godavari District, India /3-Department of Hospital and Health Care Administration, Acharya Nagarjuna University, PIPS, Andhra Pradesh, West Godavari District, India /4-Department of Scientific Medical Journal Publication, Acharya Nagarjuna University, PIPS, Andhra Pradesh, West Godavari District, India /5-National Institute of Medical Science, Acharya Nagarjuna University, PIPS, Andhra Pradesh, West Godavari District, India 

DOI:

https://doi.org/10.31661/gmj.vi.3763

Keywords:

Hutchinson-Gilford Progeria Syndrome; Lamin A; oral Manifestations

Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder caused by a point mutation in the LMNA gene that encodes lamin A. This mutation results in the production of progerin, a defective protein that accelerates cellular aging. This review explores the oral and dental manifestations of HGPS, emphasizing their role in early diagnosis, management strategies, and the potential for targeted therapies. A thorough review of existing literature was conducted to summarize the phenotypic characteristics, oral health implications, and current approaches for the management of HGPS-related complications. Individuals with HGPS exhibit age-associated complications starting in early childhood, including distinct craniofacial abnormalities and severe oral health challenges. Common oral manifestations include delayed tooth eruption, microdontia, malocclusion, dental caries, tooth loss, and mandibular osteolysis. These abnormalities necessitate a multidisciplinary approach involving pediatric dentists, orthodontists, oral surgeons, and geneticists to deliver comprehensive care. Understanding the pathophysiological mechanisms behind HGPS oral anomalies is vital for improving diagnosis and treatment. Advances in genetic research hold promise for developing targeted interventions to alleviate dental complications and enhance the quality of life for affected individuals. Ongoing research and a collaborative care approach are essential to address the challenges posed by HGPS effectively.

References

Gordon G. Communication, vision, and mission: leadership through trust. Cham: Palgrave Macmillan; 2017.

https://doi.org/10.1007/978-3-319-56955-0_5

PMCid:PMC5535293

Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin A truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628):2055.

https://doi.org/10.1126/science.1084125

PMid:12702809

Gordon LB, Rothman FG, Lopez-Otin C, Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014;156(1-2):400-7.

https://doi.org/10.1016/j.cell.2013.12.028

PMid:24485450 PMCid:PMC6318797

Dorado B, Andres V. A-type lamins and cardiovascular disease in premature aging syndromes. Curr Opin Cell Biol. 2017;46:17-25.

https://doi.org/10.1016/j.ceb.2016.12.005

PMid:28086161

Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358(6):592-604.

https://doi.org/10.1056/NEJMoa0706898

PMid:18256394 PMCid:PMC2940940

Hamczyk MR, Villa-Bellosta R, Quesada V, Gonzalo P, Vidak S, Nevado RM, et al. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells. EMBO Mol Med. 2019;11(4):e9736.

https://doi.org/10.15252/emmm.201809736

PMid:30862662 PMCid:PMC6460349

Coutinho HD, Falcao-Silva VS, Goncalves GF, Nobrega RB. Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a model. Immun Ageing. 2009 Apr 20;6:4.

https://doi.org/10.1186/1742-4933-6-4

PMid:19379495 PMCid:PMC2674425

Winter-Vann AM, Baron RA, Wong W, Cruz J, York JD, Gooden DM, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A. 2005;102(12):4336-41.

https://doi.org/10.1073/pnas.0408107102

PMid:15784746 PMCid:PMC555472

Hamczyk MR, Del Campo L, Andres V. Aging in the cardiovascular system: lessons from Hutchinson-Gilford progeria syndrome. Annu Rev Physiol. 2018;80:27-48.

https://doi.org/10.1146/annurev-physiol-021317-121454

PMid:28934587

Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006;140(23):2603-24.

https://doi.org/10.1002/ajmg.a.31346

PMid:16838330

Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2005;102(40):14416-21.

https://doi.org/10.1073/pnas.0503712102

PMid:16186497 PMCid:PMC1242289

Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012;4(144):144ra103.

https://doi.org/10.1126/scitranslmed.3003802

PMid:22837538 PMCid:PMC3613228

Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR, et al. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J Clin Invest. 2011;121(7):2833-44.

https://doi.org/10.1172/JCI43578

PMid:21670498 PMCid:PMC3223819

Harhouri K, Navarro C, Depetris D, Mattei MG, Nissan X, Cau P, et al. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation. EMBO Mol Med. 2017;9(9):1294-313.

https://doi.org/10.15252/emmm.201607315

PMid:28674081 PMCid:PMC5582415

Varela I, Pereira S, Ugalde AP, Navarro CL, Suarez MF, Cau P, et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008;14(7):767-72.

https://doi.org/10.1038/nm1786

PMid:18587406

Rivera-Torres J, Calvo CJ, Llach A, Guzman-Martinez G, Caballero R, Gonzalez-Gomez C, et al. Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. Proc Natl Acad Sci U S A. 2016;113(25):7250-9.

https://doi.org/10.1073/pnas.1603754113

PMid:27799555 PMCid:PMC5135377

Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-78.

https://doi.org/10.1016/j.cell.2022.11.001

PMid:36599349

Scharner J, Brown CA, Bower M, Iannaccone ST, Khatri IA, Escolar D, et al. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat. 2011;32(2):152-67.

https://doi.org/10.1002/humu.21361

PMid:20848652

Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, et al. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis. 2009;15(3):187-95.

https://doi.org/10.1111/j.1601-0825.2009.01521.x

PMid:19236595 PMCid:PMC2664390

Maloney WJ. The dental and oral significance of Hutchinson-Gilford progeria syndrome. Arch Dent. 2018;1(1):4-6.

https://doi.org/10.33696/dentistry.1.002

Pollex RL, Hegele RA. Hutchinson-Gilford progeria syndrome. Clin Genet. 2004;66(5):375-81.

https://doi.org/10.1111/j.1399-0004.2004.00315.x

PMid:15479179

Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, et al. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis. 2009;15(3):187-95.

https://doi.org/10.1111/j.1601-0825.2009.01521.x

PMid:19236595 PMCid:PMC2664390

Marcos-Ramiro B, Gil-Ordonez A, Marin-Ramos NI, Ortega-Nogales FJ, Balabasquer M, Gonzalo P, et al. Isoprenylcysteine carboxylmethyltransferase-based therapy for Hutchinson-Gilford progeria syndrome. ACS Cent Sci. 2021;7(9):1560-72.

https://doi.org/10.1021/acscentsci.0c01698

PMid:34471675 PMCid:PMC8393201

Macicior J, Marcos-Ramiro B, Ortega-Gutierrez S. Small-molecule therapeutic perspectives for the treatment of progeria. Int J Mol Sci. 2021;22(13):7190.

https://doi.org/10.3390/ijms22137190

PMid:34281245 PMCid:PMC8267806

Downloads

Published

2025-01-20

How to Cite

Saeed, S., Abdulaziz Alhababi , J., Alanazi, F., Albarrak, A., Alabdulmonem, H., Inad Alenazi, A., … Akshay Kiran , M. (2025). The Dental and Oral Significance of Hutchinson-Gilford Prfogeria Syndrome. Galen Medical Journal, 14(SP1), e3763. https://doi.org/10.31661/gmj.vi.3763

Issue

Vol. 14 No. SP1 (2025): Head and Neck Disorders: From Molecular Insights to Surgical Breakthroughs

Section

Review Article

License

Copyright (c) 2025 Galen Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

https://creativecommons.org/licenses/by/4.0/